Can a targeted drug extend life in Hard-to-Treat breast cancer?

NCT ID NCT06993506

NEW Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This study looks at how well sacituzumab tirumotecan (SKB264) works, either alone or with other treatments, in people with advanced HER2-negative breast cancer that has spread or come back. It includes two groups: those with triple-negative breast cancer and those with hormone receptor-positive, HER2-negative disease. The goal is to see how long patients go before needing a different treatment and to check the drug's safety in everyday clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab tirumotecan (SKB264) given alone or with other drugs
What this could lead to: If successful, this could provide a new treatment option for advanced HER2-negative breast cancer, potentially improving how long patients live without the disease progressing.
What could go wrong: This is an observational study, so it cannot prove the drug works better than existing treatments. Results may vary in real-world settings, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Her2-receptor negative breast cancer hormone receptor-positive breast cancer metastatic neoplasm Neoplasm Metastasis Recurrence triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-NEGATIVE BREAST CANCER METASTASIS RECURRENCE

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China
Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100853, China
Fujian Cancer Hospital
NOT_YET_RECRUITING

Fuzhou, Fujian, 350000, China
Hubei Cancer Hospital
NOT_YET_RECRUITING

Wuhan, Hubei, 430079, China
Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China
Shanxi Bethune Hospital
RECRUITING

Taiyuan, Shanxi, 030032, China
Suining Central Hospital
RECRUITING

Suining, Sichuan, 629000, China
Taihe Hospital
RECRUITING

Shiyan, Hubei, 442099, China
The Affiliated People's Hospital of Ningbo University
RECRUITING

Ningbo, Zhejiang, 315100, China
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITING

Xiamen, Fujian, China
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITING

Zhengzhou, Henan, China
The First People's Hospital of Changde City
RECRUITING

Changde, Hunan, 415003, China
The Fourth Hospital of Hebei Medical University
NOT_YET_RECRUITING

Shijiazhuang, Hebei, China
The Second Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, Anhui, 230601, China
The Third People's Hospital of Zhengzhou
NOT_YET_RECRUITING

Zhengzhou, Henan, 450000, China
The first hospital of Jilin University
RECRUITING

Changchun, Jilin, 130021, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
NOT_YET_RECRUITING

Wuhan, Hubei, 430022, China
Yantai Yuhuangding Hospital
RECRUITING

Yantai, Shandong, 264000, China
Zhongshan Hospital Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.